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Background: Histone H3 methylation at lysine 9 (H3K9) is a conserved epigenetic signal, mediating heterochromatin
formation by trimethylation, and transcriptional silencing by dimethylation. Defective GLP (Ehmt1) and G9a (Ehmt2)
histone lysine methyltransferases, involved in mono and dimethylation of H3K9, confer autistic phenotypes and
behavioral abnormalities in animal models. Moreover, EHMT1 loss of function results in Kleefstra syndrome, characterized
by severe intellectual disability, developmental delays and psychiatric disorders. We examined the possible role of
histone methyltransferases in the etiology of autism spectrum disorders (ASD) and suggest that rare functional variants
in these genes that regulate H3K9 methylation may be associated with ASD.
Methods: Since G9a-GLP-Wiz forms a heteromeric methyltransferase complex, all the protein-coding regions and
exon/intron boundaries of EHMT1, EHMT2 and WIZ were sequenced in Japanese ASD subjects. The detected variants
were prioritized based on novelty and functionality. The expression levels of these genes were tested in blood cells
and postmortem brain samples from ASD and control subjects. Expression of EHMT1 and EHMT2 isoforms were
determined by digital PCR.
Results: We identified six nonsynonymous variants: three in EHMT1, two in EHMT2 and one in WIZ. Two variants, the
EHMT1 ankyrin repeat domain (Lys968Arg) and EHMT2 SET domain (Thr961Ile) variants were present exclusively in cases,
but showed no statistically significant association with ASD. The EHMT2 transcript expression was significantly elevated in
the peripheral blood cells of ASD when compared with control samples; but not for EHMT1 and WIZ. Gene expression
levels of EHMT1, EHMT2 and WIZ in Brodmann area (BA) 9, BA21, BA40 and the dorsal raphe nucleus (DoRN) regions
from postmortem brain samples showed no significant changes between ASD and control subjects. Nor did expression
levels of EHMT1 and EHMT2 isoforms in the prefrontal cortex differ significantly between ASD and control groups.
Conclusions: We identified two novel rare missense variants in the EHMT1 and EHMT2 genes of ASD patients. We
surmise that these variants alone may not be sufficient to exert a significant effect on ASD pathogenesis. The elevated
expression of EHMT2 in the peripheral blood cells may support the notion of a restrictive chromatin state in ASD, similar
to schizophrenia.
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Autism spectrum disorders (ASD), characterized by de-
fects in social reciprocity, impairment in communication
and restricted and repetitive stereotyped behavioral
patterns, are the most prevalent childhood neurode-
velopmental disorders. They affect all racial, ethnic and
socioeconomic groups equally, with a worldwide preva-
lence of approximately 0.6% [1,2]. The genetic influences
in the etiology of ASD have been demonstrated in family
and twin studies [3,4], along with discoveries of common
and rare genetic variants and pronounced chromosomal
abnormalities [5]. Recently, de novo rare variants with a
large effect size were found to increase ASD susceptibility
[6,7]. However, generation of the ASD phenotype re-
quires interaction between environmental factors, and
inherited and de novo genetic variants [8]. Furthermore,
the pivotal role of epigenetic regulatory mechanisms in-
volved in the pathogenesis of Rett syndrome, fragile X
syndrome and the identification of ASD-associated gen-
etic defects in imprinted regions lends strength to the
hypothesis that epigenetic factors are causative in ASD
etiology [9].
Epigenetic mechanisms involving post translational
modification of histone lysine methylation influence nu-
merous biological processes, including transcription,
replication and chromosome maintenance, all of which
are tightly regulated by methyltransferases and demethy-
lases [10]. Among them, methylation of lysine 9 in his-
tone H3 (H3K9), marks a conserved epigenetic signal;
by heterochromatin formation through trimethylation
(H3K9me3) and transcriptional silencing through dimethy-
lation (H3K9me2) [11]. The formation of H3K9me1 and
H3K9me2 are mediated by a Suv39h subgroup of histone
methyl transferases, namely G9a/KMT1C and GLP/
KMT1D, both having Su(var)3-9-Enhancer of zeste-
Trithorax (SET) domain, through which they form homo-
meric and heteromeric complexes [12]. The G9a-GLP
heteromeric complex is known to interact with Wiz,
a multi-zinc finger-containing molecule, resulting in a
stable and dominant intracellular heteromeric methyl-
transferase complex [13].
Regulation of H3K9 methylation has a powerful im-
pact on neurological function and disease, as exemplified
in Kleefstra syndrome. This disease is characterized by
severe intellectual disability, developmental delay and
psychiatric disorders, and is the result of a 9q34 subtelo-
meric deletion and loss-of-function mutations in EHMT1
[14,15]. In Ehmt1 heterozygous knockout mice, the typical
autistic-like features including reduced exploration, in-
creased anxiety, altered social behavior, deficits in fear ex-
tinction, and learning and object recognition (novel and
spatial) are observed [16,17]. Furthermore, the lack of post-
natal and neuron-specific GLP/G9a expression in mouse
models dysregulates neuronal transcriptional, resulting inbehavioral abnormalities, such as impaired learning, motiv-
ation and environmental adaptation [18].
Therefore, the autistic-like features and behavioral ab-
normalities precipitated by defects in histone methyl-
transferases provide a powerful case for examining their
involvement in ASD pathogenesis. We put forward that
rare functional variants in these genes may be associated
with ASD. Since G9a-GLP-Wiz forms a stable and dom-
inant heteromeric methyltransferase complex in H3K9
methylation, we set out to resequence the EHMT1,
EHMT2 and WIZ genes coding for GLP, G9a and WIZ,
respectively, in Japanese ASD case and control samples.
Methods
Subjects
A cohort of 315 patients of Japanese descent, with aut-
ism (262 males and 53 females, mean age ± SD =12.09 ±
5.72 years), comprising 293 independent subjects and
affected siblings, were recruited for the resequencing
studies. The diagnosis of autism was made using the
Diagnostic and Statistical Manual, Fourth Edition, Text
Revision (DSM-IV-TR: American Psychiatric Association,
2000) criteria. The Autism Diagnostic Interview-Revised
(ADI-R) [19] was conducted by experienced child psy-
chiatrists who are licensed to use the Japanese version
of the ADI-R. Participants with comorbid psychiatric
illnesses were excluded by means of the Structured
Clinical Interview for DSM-IV (SCID) [20]. Control
subjects (n =1,140, 440 males and 700 females, mean
age ± SD =44.10 ± 13.63 years) devoid of any past or
present psychiatric disorders were recruited from hos-
pital staff and company employees. Samples were also
collected from available parents of subjects who harbored
novel mutations, in order to determine whether these
mutations were de novo. All participants were provided
with, and received a full explanation of study protocols
and objectives, before giving informed, written con-
sent to participate in the study. For patients under
the age of 16 years, written informed consent was also
obtained from their parents. The study was approved
by the Ethics Committees of RIKEN and Hamamatsu
University School of Medicine, and conducted according
to the principles expressed in the Declaration of Helsinki.
DNA was extracted from whole blood according to a
standard protocol.
A subset of subjects, 52 ASD (43 males and 9 females,
mean age ± SD =11.98 ± 2.43) and 32 normal controls
(26 males and 6 females, mean age ± SD =12.31 ± 2.01),
was selected to analyze transcript expression levels in
peripheral blood cells from the cohort whose DNA was
resequenced for the candidate genes. Postmortem brain
tissues from ASD and age-matched control samples were
obtained from the National Institute of Child Health
and Human Development (NICHD) Brain and Tissue
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medschool.umaryland.edu/btbank/), for gene expression
analysis (Additional file 1: Table S1). Frozen tissue samples
from BA09 (ASD; n =10, control; n =10), BA21 (ASD;
n =14, control; n =14), BA40 (ASD; n =14, control; n =13)
and DoRN regions (ASD; n =8, control; n =8) were
used in this study. Total RNA from peripheral blood
cells and brain tissues was extracted using a miRNAeasy
Mini kit (QIAGEN GmbH, Hilden, Germany) and
single stranded cDNA was synthesized using a SuperScript
VILO cDNA synthesis kit (Life Technologies Co., Carlsbad,
CA, USA), according to the manufacturers’ instructions.
Resequencing and variant analysis
Protein-coding regions and exon/intron boundaries of
EHMT1, EHMT2 and WIZ were screened for variants in
ASD case samples by direct sequencing of PCR prod-
ucts, using the BigDye Terminator v3.1 cycle Sequencing
Kit (Applied Biosystems (ABI), Foster City, CA, USA),
and analyzed on an ABI3730 Genetic Analyzer (ABI),
using standard protocols. The primers used for amplifi-
cation and PCR conditions are listed in Additional file 2:
Table S2. The sequences were aligned to the respect-
ive reference sequences (EHMT1 isoform 1: RefSeq
NM_024757.4, Isoform 2: RefSeq NM_001145527.1,
EHMT2 isoform a: RefSeq NM_006709.3, isoform b:
RefSeq NM_25256.5, and WIZ: RefSeq NM_021241.2) and
variants were detected using Sequencher software (Gene
Codes Corporation, Ann Arbor, MI, USA). For the hetero-
zygous variant calls in Sequencher, the height of the sec-
ondary peak was set at 35% of the primary peak and all
variants were confirmed by bidirectional sequencing of
the sample.
Variants were prioritized based on whether they were,
(i) located in an important functional domain of the pro-
tein, (ii) deemed to be functional, such as a frame shift,
stop gain or nonsynonymous mutation, and (iii) novel,
that is not documented in the NCBI dbSNP database
(Build 137) (http://www.ncbi.nlm.nih.gov/SNP/), the 1000
Genomes Project (http://www.1000genomes.org/), the
Exome Variant Server of NHLBI GO Exome Sequencing
Project (ESP6500SI-V2) (http://evs.gs.washington.edu/
EVS/) or the Human Genetic Variation Database of
Japanese genetic variation consortium (http://www.
genome.med.kyoto-u.ac.jp/SnpDB). The potential func-
tional consequences of variants were evaluated in silico,
using PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/),
PROVEAN (http://provean.jcvi.org/index.php) and SIFT
(http://sift.jcvi.org/). In the control samples, we screened
only exons coding for functional domains of the candidate
genes (Figure 1 and Additional file 3: Figure S1 (A)).
Fisher’s exact test (two-tailed) was used to compare the dif-
ferences in allele counts between ASD and control sub-
jects, with statistical significance being defined as P <0.05.Gene expression analysis
Real-time quantitative RT-PCR analysis was conducted
using standard procedures, in an ABI7900HT Fast Real-
Time PCR System (ABI, Foster City, CA, USA). TaqMan
probes and primers for EHMT1, EHMT2 and WIZ and
GAPDH (internal control) were chosen from TaqMan
Gene Expression Assays (ABI, Foster City, CA, USA)
(Figure 1 and Additional file 4: Table S3). All real-time
quantitative RT-PCR reactions were performed in tripli-
cate, based on the standard curve method. To check
for isoform-specific expressional changes between ASD
cases and controls (prefrontal cortex), digital PCR was
performed using standard procedures for EHMT1 (vari-
ant 1: NM_024757.4 and variant 2: NM_001145527.1)
and EHMT2 (isoform a: NM_006709.3 and isoform b:
NM_025256.5) isoforms, using TaqMan Gene Expres-
sion Assays in a QuantStudio12K Flex Real-Time PCR
System (Life Technologies Co., Carlsbad, CA, USA)
(Figure 1 and Additional file 4: Table S3). Significant
changes in target gene expression levels between the
cases and controls were detected by Mann–Whitney
U-test (two-tailed) and P values of <0.05 were con-
sidered statistically significant.
Results
Resequencing and genetic association analyses
Resequencing of the coding regions and exon/intron
boundaries of the three genes, yielded several novel
and previously reported variants in the ASD cohort,
with varying minor allele frequencies (Additional file 5:
Table S4). Filtering of variants based on functionality
(nonsynonymous and frameshift) and novelty, revealed
three nonsynonymous variants in EHMT1, two nonsy-
nonymous variants in EHMT2 and one nonsynonymous
variant in WIZ (Table 1). All variants showed low minor
allele frequencies (MAF <0.01) and were deemed to be
inherited from the parents, although this could not
be confirmed in cases bearing the EHMT1 variant,
Lys968Arg, due to a lack of parental samples for testing
(Figure 2).
Since histone methylation is effected through the for-
mation of multimeric complexes of histone methyltrans-
ferases, which in turn are mediated by interaction of
functional domains, we focused our interests on these
regions. Results revealed that rare variants in the EHMT1
ankyrin repeat domain (Lys968Arg) and EHMT2 SET do-
main (Thr961Ile) were present in ASD cases but not in
any of the 1,140 screened control subjects. Examining the
cases, we observed no variations in the functional domains
of WIZ. The case–control comparison showed no statisti-
cally significant association of any identified variants with
ASD (Table 2). In addition, we also identified EHMT1 and
EHMT2 variants that were present only in the control
population (Additional file 4: Table S4).
Figure 1 Genomic structures of EHMT1, EHMT2 and WIZ genes screened in Japanese autism spectrum disorder (ASD) subjects, and
identified missense variants. Black boxes denote coding exons and white boxes denote non-coding exons.
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EHMT1 9,140611506,C,T Exon3 c.514C > T p.Pro172Ser - 2 - Possibly damaging Neutral Damaging
EHMT1 9,140638415,C,T Exon6 c.1,043C > T p.Ser348Leu - 2 - Possibly damaging Deleterious Damaging
EHMT1 9,140707493,A,G Exon20 c.2,903A > G p.Lys968Arg ANK repeat
domain
1 0 Possibly damaging Neutral Tolerated
EHMT2 6,31857330,C,- Exon8 c.913_915delGGA p.Glu305del - 1 - NA NA NA
EHMT2 6,31851617,G,A Exon22 c.2,882C > T p.Thr961Ile SET domain 1 0 Possibly damaging Neutral Tolerated
WIZ 19,15535180,C,T Exon7 c.2,039G > A p.Arg680His - 1 - Probably damaging Neutral Damaging
Legend: ‘-’ denotes that the corresponding variant was not examined in control samples because it was located outside of a functional domain; ANK, ankyrin
repeat domain; SET, Su(var)3-9-Enhancer of zeste-Trithorax domain.
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The EHMT2 transcript expression was significantly el-
evated in the peripheral blood cells of ASD when
compared with control samples (P =0.02) (Figure 3B).
But the EHMT1 and WIZ levels were not signifi-
cantly different between the ASD and control groups
(Figure 3A, C). The gene expression analysis of
EHMT1, EHMT2 and WIZ in BA09, BA21, BA40 and
DoRN regions from postmortem samples, showed no
significant changes in expression levels between ASD and
control groups (Figure 4A, B, C). We further examined
the expression of EHMT1 and EHMT2 isoforms in the
prefrontal cortex (BA09) of ASD patients. The EHMT1
variant 1 (NM_024757.4) and EHMT2 isoform a
(NM_006709.3) were highly expressed compared to alter-
native isoforms. However, there was no significant differ-
ence in expression levels of these isoforms in the prefrontalFigure 2 Pedigree structures of autism spectrum disorder (ASD) fami
With the exception of Lys968Arg, none of the novel variants were de novo
not available.cortex, when the ASD cases were compared to controls
(Figure 4D).
Discussion
Disruption of histone lysine methylation plays an im-
portant role in the pathogenesis of neurological disor-
ders and cancer, as evidenced by the reports of genomic
aberrations in histone methyltransferases in these dis-
eases [10]. Since defective G9a and GLP histone lysine
methyltransferases, give rise to autistic phenotypes [21],
we searched for loss of function variants in the genes
involved in H3K9 methylation, concentrating on rare
mutations that show enrichment in ASD subjects. We
focused on the variants located in the functional do-
mains that are important in the formation of multimeric
enzyme complex, and we identified the EHMT1 ankyrin
repeat domain variant (Lys968Arg) and EHMT2 SETlies harboring novel missense variants in EHMT1, EHMT2 and WIZ.
. For the Lys968Arg variant, genotype information of the father was
Table 2 Comparison of genotype and allele frequencies of EHMT1 and EHMT2 missense variants between autism
spectrum disorder (ASD) cases and controls
Gene Variant Subject Genotype P-value Allele P-value MAFa (%)
EHMT1 c.2903A > G A/A A/G G/G A G G
Lys968Arg Autism 292 1 0 0.14 585 1 0.46 0.170
(ANK repeat domain) Control 1,139 0 0 2,278 0 0
EHMT2 c.2882C > T C/C C/T T/T C T T
Thr961Ile Autism 292 1 0 0.14 585 1 0.46 0.170
(SET domain) Control 1,139 0 0 2,278 0 0
aMAF: minor allele frequency. ANK, ankyrin repeat domain; SET, Su(var)3-9-Enhancer of zeste-Trithorax domain.
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ASD cases and not in 1,140 control subjects. Although
these two mutations were found exclusively in cases,
case–control comparisons found no statistically signifi-
cant association. Thus, our results did not support a role
for these rare variants in ASD. This is in keeping with in
silico analyses which predicted that the effects for both
the EHMT1 (Lys968Arg) and EHMT2 (Thr961Ile) muta-
tions would to be ‘neutral’ and ‘tolerated’ by Provean
and SIFT, respectively, although PolyPhen2 predicted a
‘possibly damaging’ phenotype.
Since a large number of ‘loss of function’ variants are
present in healthy human genomes [22], we speculate
that the variants we identified may be private, owing
to their lack of ‘predicted functional defects’, consistent
through the three algorithms. On the other hand, balanced
chromosomal abnormalities seen in ASD and related neu-
rodevelopmental disorders are reported to disrupt the
EHMT1 gene [23]. In addition, a de novo deletion and rare
inherited loss of function mutation in EHMT1 were ob-
served in a sporadic ASD trio sample [24] and in ASD
families [25], respectively. It is clear that to understand the
exact role of our identified variants, it will be necessary to
examine them using much larger sample sets and more
sophisticated functional assessments.
Interestingly, we observed an overexpression of the
EHMT2 gene in peripheral blood cells from ASD patientsFigure 3 Expression analysis of (A) EHMT1, (B) EHMT2 and (C) WIZ in l
(ASD) cases and control (CNT) subjects who were resequenced for thepointing towards a role of restricted chromatin state in
ASD pathogenesis. A recent study showed increased ex-
pression of the EHMT2 gene in lymphocytes and the
EHMT1 gene in both postmortem parietal cortex and
lymphocyte samples, from patients with schizophrenia
[26]. The study also found that a diagnosis of schizo-
phrenia was a significant predictor for increased expres-
sion of histone methyltransferases. Therefore, the present
results are interesting, given the genetic overlap between
schizophrenia and ASD [27]. However, no significant
changes in the expression levels of EHMT1, EHMT2
or WIZ were observed in the postmortem brain samples
from BA09, BA21, BA40 and DoRN region, between
ASD subjects and controls. Additionally, we detected no
differential expression of EHMT1 and EHMT2 isoforms
in the prefrontal cortex (BA09) between the two subject
groups. The results suggest an absence of common vari-
ants in the regulatory genomic elements of these genes
associated with ASD.
Mutations in the chromatin remodeling enzymes have
been reported in psychiatric diseases, which disrupt the
chromatin regulation leading to altered neuronal func-
tion and behavioral abnormalities [28]. But in our study,
such a loss of function mutation was not observed.
Moreover, the identified mutations did not have a cogent
effect in ASD pathogenesis, either through functional
deficits or changes in expression levels. Therefore, itymphocyte samples from a subset of autism spectrum disorder
candidate genes.
Figure 4 Gene expression analysis of (A) EHMT1, (B) EHMT2 and (C) WIZ in Brodmann area (BA) 09, BA21, BA40 and DoRN (dorsal
raphe nucleus) of autism spectrum disorder (ASD) cases and controls (CNT). (D) Isoform-specific expression analysis of EHMT1 (variant 1:
NM_024757.4 and variant 2: NM_001145527.1) and EHMT2 (isoform a: NM_006709.3 and isoform b: NM_025256.5) in the prefrontal cortex (BA09)
of ASD cases and controls.
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in histone methyltransferases may constitute a rare
event in ASD pathogenesis, which is supported by
the fact that H3K9 modifying enzymes have fewer re-
ported mutations, when compared to other chromatin
regulators [29].
Since EHMT2 overexpression correlates with the
increased H3K9me2 levels [30], it could result in the
repressed transcription of the genes/genetic network
relevant to ASD pathogenesis. However, the results from
expression analysis of peripheral blood cells should be
interpreted cautiously because peripheral blood chroma-
tin may not essentially provide information specific to a
brain region or neuronal phenotype [31]. Future studies
are warranted to profile the global H3K9 (mono and di)
methylation status in ASD brain to delineate the genetic
networks, which are dysregulated in ASD.Although the present study did not show statisti-
cally significant enrichment of variants in ASD, their
possible contribution to disease cannot be ruled out,
due to the relatively small sample size restricting the
statistical power of this study and also the absence of
identified patient-specific mutations in global data-
bases for the control population. From the available
three-dimensional structures, it would appear that both
mutations are located on the surface of the proteins
(Additional file 3: Figure S1 (B and C), implying a po-
tential role for the variants in complex formation. Re-
cent whole genome and exome sequencing studies have
clearly shown a heterogeneous genetic basis for ASD
and have identified a large number of candidate genes,
converging on functional pathways of neuronal signaling
and development, synapse function and chromatin regu-
lation [32]. It is also known that SETDB1 and Suv39h1
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with interdependent functionality [33]. Therefore, the
polygenic burden of ASD may mask the effects of single
rare variants, obscuring their individual contribution to
disease pathogenesis [34].
Conclusion
In summary, we identified two novel, rare missense vari-
ants in the EHMT1 and EHMT2 genes from ASD pa-
tients. We surmise that these variants alone may not be
sufficient to exert a significant effect on ASD pathogen-
esis and that a concerted interaction with additional gen-
etic or epigenetic effects may be needed to manifest the
disease phenotype. The elevated expression of EHMT2
observed in peripheral blood cells from ASD patients
may support the notion of a restrictive chromatin state
in ASD pathogenesis, similar to schizophrenia. Future
studies with larger sample sizes and sophisticated func-
tional assessments are warranted to define the precise
role of EHMT1 and EHMT2 in ASD pathogenesis.
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Additional file 1: Table S1. Demographic details of autism spectrum
disorder (ASD) and control brain samples from the NICHD Brain and
Tissue Bank, University of Maryland School of Medicine (http://medschool.
umaryland.edu/btbank/).
Additional file 2: Table S2. PCR amplification primers and conditions.
Additional file 3: Figure S1. (A) Domain structure of EHMT1 (GLP)
and EHMT2 (G9a), indicating mutated and their conserved positions,
(B) three-dimensional structure of EHMT1 (GLP), and (C) three-dimensional
structure of EHMT2 (G9a). The structural data were obtained from Protein
Data Bank (http://www.rcsb.org/pdb/home/home.do) and visualized using
the UCSF Chimera package (http://www.cgl.ucsf.edu/chimera/) for
determining the position of identified variants. The EHMT1/GLP complex
(PDB entry: 3B95) contains three peptide chains, where the A and B chains
are from GLP, and the P chain is a histone H3 N-terminal peptide. The B
chain (blue), P chain (green) and the variant (red) are shown in figure (B).
The mutation is located on the surface of the protein. The EHMT2/G9a
complex (PDB entry: 3K5K) contains two SET domains from G9a (A and
B chains). The A chain is shown here in (C) with ligands DXQ (7-[3-
(dimethylamino) propoxy]-6-methoxy-2- (4-methyl-1,4-diazepan-1-yl)-
N-(1-methylpiperidin-4-yl)quinazolin-4-amine) and S-adenosyl-L-homocysteine
marked in green and cyan, respectively. The variant position (red) is located
on the surface of the protein, away from substrate binding sites.
Additional file 4: Table S3. List of TaqMan assay IDs used for gene
expression studies.
Additional file 5: Table S4. Novel and previously reported variants in
the ASD cohort and variants specific to the control population.
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